SCHEMBL8282923

SCHEMBL8282923

CON(C)C(=O)c1cc(Br)nc(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.41
CLK1 P49759 2/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
TRPM8 Q7Z2W7 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NCEH1 Q6PIU2 2/20 0.33
PTGS2 P35354 1/20 0.33
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
SLC6A3 Q01959 1/20 0.33
POLB P06746 1/20 0.32
HPGDS O60760 2/20 0.32
AKT1 P31749 1/20 0.31
AKT2 P31751 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17005394 0.85 MLYCD (0.43) MLYCD
SCHEMBL19330134 0.81 KDM4E (0.56) MLYCDCLK1DYRK1ADYRK1BKMT2A
SCHEMBL7077559 0.81 MLYCD (0.44) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL4778395 0.81 MLYCD (0.44) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL29632636 0.80 SMN1; SMN2 (0.41) MEN1KMT2ATDP1KDM4EALDH1A1
SCHEMBL39608 0.80 MLYCD (0.41) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL361909 0.79 MLYCD (0.42) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL1367620 0.78 MLYCD (0.41) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL24664552 0.76 MLYCD (0.44) MLYCDCLK1DYRK1ADYRK1BMEN1
SCHEMBL15100737 0.76 MLYCD (0.41) MLYCDCLK1DYRK1ADYRK1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043435-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2024-02-08 US disclosed
EP-4168398-A1 TYK-2 INHIBITOR BeiGene, Ltd. (KY) 2023-04-26 EP disclosed
CN-115715288-A TYK-2 inhibitors 百济神州有限公司 2023-02-24 CN disclosed
WO-2021259208-A1 TYK-2 INHIBITOR BEIGENE, LTD. (KY) 2021-12-30 WO disclosed
WO-2005084439-A1 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES DOV PHARMACEUTICAL, INC. (US) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043435-A1 TYK-2 INHIBITOR TYK2, IRAK2, PTK2B MLYCD 2291/4885CLK1 539/4885DYRK1A 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.